Added to YB: 2026-03-24
Pitch date: 2026-03-19
RVPH [neutral]
Reviva Pharmaceuticals Holdings, Inc.
+6.09%
current return
Author Info
No bio for this author
Company Info
Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases.
Market Cap
$5.2M
Pitch Price
$0.84
Price Target
N/A
Dividend
N/A
EV/EBITDA
N/A
P/E
-0.09
EV/Sales
N/A
Sector
Pharmaceuticals
Category
turnaround
RVPH (Reviva Pharmaceuticals) - Where It All Started
RVPH (exited position): Announced dilutive offering after reverse split to stay listed, stock crashed 39% to $1.14. FDA requested another Phase 3 for brilaroxazine (schizophrenia) but company lacks funding. Author reflects on early lessons learned that shaped current scoring system for cash runway, dilution risk & catalyst diversification.
Read full article (2 min)